期刊
ONCOIMMUNOLOGY
卷 3, 期 5, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.28927
关键词
immunosuppression; tryptophan; glioblastoma; metabolism; immunotherapy
资金
- NCATS NIH HHS [UL1 TR000430] Funding Source: Medline
- NCI NIH HHS [R01 CA138587, R01 CA122930] Funding Source: Medline
- NINDS NIH HHS [F32 NS073366, R00 NS082381, U01 NS069997, K99 NS082381] Funding Source: Medline
Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据